WELCOME TO SENTINEL PLUS
This medical education website has been funded by AstraZeneca and co-developed with Hull University Teaching Hospitals NHS Trust. This website is intended for UK healthcare professionals only.
THE
SENTINEL
PLUS STORY
Find out more in the videos below about the inspiration behind the original SENTINEL quality improvement project, the impact it made and the SENTINEL Plus quality improvement framework.
You can also learn more in the SENTINEL Plus prospectus here:
THE ASTHMA CHALLENGE
THE SENTINEL
PILOT
INTRODUCING SENTINEL PLUS
GB-76597 | May 2026
THE ASTHMA CHALLENGE
This video describes the risks of SABA over-use and the alignment to reducing SABA over-use provided by the 2024 BTS/NICE/SIGN asthma guidelines, which move away from SABA reliever inhalers and towards anti-inflammatory based reliever inhalers for eligible new and uncontrolled asthma patients.
THE SENTINEL PILOT
The results from the 2020 SENTINEL project pilot PCN demonstrate the potential impact that supported guideline implementation can have to deliver sustained results in reducing SABA over-reliance in asthma.
This video discusses the initial results from the implementation of the SENTINEL quality improvement initiative in the Hull and East Yorkshire region, across a population of 2,500 registered asthma patients.
INTRODUCING SENTINEL PLUS
Based on the positive results of the original SENTINEL quality improvement initiative, the SENTINEL Plus quality improvement framework was developed to support other regions across the UK to improve outcomes for asthma patients.
Find out more about how the SENTINEL Plus package was co-designed in this video.
SENTINEL Plus is developed with the aim of improving outcomes for asthma patients through identifying and addressing short-acting beta 2 agonist (SABA) over-reliance
GB-76210 | May 2026